Condition: Hemophilia A · Sponsor: Emory University
This is a non-interventional, multicenter, observational, international study in male persons with haemophilia A who have developed inhibitors to any replacement coagulation factor VIII (FVIII) product. The purpose of the study is to capture different approaches in the management of persons with haemophilia A and FVIII inhibitors, document current immune tolerance induction approaches, and evaluate the efficacy and safety of immune tolerance induction, including the combination of FVIII and emicizumab. Patients will be assigned to 1 of 3 groups based on the treatments they receive, and may switch to another group if their treatment is changed. Participants will be followed after a maximum observational period of 5 years.
This description comes directly from the study's public registry record.
Robert Sidonio, MD, MSc · 404-785-1637 · robert.sidonio.jr@emory.edu
Carmen Escuriola-Ettingshausen, MD · +4961059638909 · carmen.escuriola@hzrm.de
Always discuss trial participation with your own doctor first.
| Arthur M. Blank Hospital | Atlanta, Georgia, United States | Recruiting |
| HZRM Hämophilie-Zentrum Rhein Main | Mörfelden-Walldorf, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04023019